<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617474</url>
  </required_header>
  <id_info>
    <org_study_id>L1386</org_study_id>
    <secondary_id>200786</secondary_id>
    <nct_id>NCT00617474</nct_id>
  </id_info>
  <brief_title>The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group</brief_title>
  <official_title>The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labbafinejhad Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Labbafinejhad Hospital</source>
  <brief_summary>
    <textblock>
      The study hypothesis is that erythropoietin usage after kidney transplantation, in early
      phase, can improve the outcome for patients and their graft increasing patient and graft
      survival.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2008</start_date>
  <completion_date type="Anticipated">March 2009</completion_date>
  <primary_completion_date type="Anticipated">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>We will study the well-being of renal function by evaluation of plasma Cr,GFR,PTDA scan &amp; biopsy proven(If it is necessary to prove the rejection)about measuring of patient - graft survival.</measure>
    <time_frame>May,2008</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Transplantation, Kidney</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group of patient with anemia, that treated by erythropoietin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients group with anemia that treated by placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hb: &gt;8 and &lt;10 gr/dl

          -  Age: &gt;18 and &lt;55 years

          -  Cholesterol: &lt;300 mg/dl

          -  Triglyceride: &lt;400 mg/dl

          -  First Transplantation

          -  Protocol of Immunosuppression: CSA + MMF + Prednisolone

          -  Systolic BP: &lt;14

          -  Diastolic BP: &lt;9

        Exclusion Criteria:

          -  History of specified cardiac disease

          -  Second Transplantation or more

          -  Hb: &lt;7gr/dl

          -  The patient needs to infusion of blood

          -  Evidence of local or systemic infection, at the time of EPO injection

          -  Presence of ATN / DGF after transplantation

          -  Presence of emergent hypertension

          -  High risk patients ( Like; PRA&gt;50%)

          -  Past history of hypersensitivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <last_update_submitted>March 27, 2008</last_update_submitted>
  <last_update_submitted_qc>March 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr.Poorrezagholi</name_title>
    <organization>Shaheed Beheshti Medical University</organization>
  </responsible_party>
  <keyword>erythropoietin</keyword>
  <keyword>kidney allograft survival</keyword>
  <keyword>Recombinant Erythropoietin</keyword>
  <keyword>erythropoietin (Epo)-induced protein 29, human</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

